<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00626509</url>
  </required_header>
  <id_info>
    <org_study_id>GICR-GIR-1</org_study_id>
    <secondary_id>CDR0000588423</secondary_id>
    <secondary_id>EUDRACT-2007-005977-67</secondary_id>
    <nct_id>NCT00626509</nct_id>
  </id_info>
  <brief_title>Sunitinib Before or After Surgery in Treating Patients With Metastatic Kidney Cancer</brief_title>
  <official_title>Sunitinib Either Before or After Cytoreductive Nephrectomy in Patients With Metastatic Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Carcinoma Renale</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth and by blocking blood flow to the tumor. Giving sunitinib before&#xD;
      surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be&#xD;
      removed. Giving it after surgery may kill any tumor cells that remain after surgery. It is&#xD;
      not yet known whether sunitinib is more effective when given before or after surgery in&#xD;
      treating kidney cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying the side effects of sunitinib and to&#xD;
      compare how well it works when given before or after surgery in treating patients with&#xD;
      metastatic kidney cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To compare the activity of sunitinib malate when administered before vs after&#xD;
           cytoreductive nephrectomy, in terms of response rate, in patients with metastatic renal&#xD;
           cell carcinoma.&#xD;
&#xD;
        -  To compare the safety of these regimens in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To compare the time to progression in patients treated with these regimens.&#xD;
&#xD;
        -  To compare the duration of response in patients treated with these regimens.&#xD;
&#xD;
        -  To compare the overall survival of patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients undergo cytoreductive nephrectomy. Patients then receive adjuvant&#xD;
           therapy comprising oral sunitinib malate once daily for 4 weeks. Treatment repeats every&#xD;
           6 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.&#xD;
           Some patients may continue treatment beyond 1 year at the discretion of the&#xD;
           investigator.&#xD;
&#xD;
        -  Arm II: Patients receive neoadjuvant therapy comprising oral sunitinib malate once daily&#xD;
           for 4 weeks. Treatment repeats every 6 weeks for 2 courses. After completion of&#xD;
           neoadjuvant therapy, patients undergo cytoreductive nephrectomy followed by adjuvant&#xD;
           sunitinib malate as in arm I.&#xD;
&#xD;
      After completion of study therapy, patients are followed every 2 months for up to 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2008</start_date>
  <primary_completion_date type="Anticipated">January 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Overall objective tumor response rate (complete response, partial response, stable disease, and progressive disease) as assessed by RECIST criteria</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events as assessed by NCI CTCAE v3.0</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Kidney Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sunitinib malate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Proven metastatic renal cell carcinoma&#xD;
&#xD;
          -  Measurable disease (according to RECIST criteria)&#xD;
&#xD;
          -  Eligible for cytoreductive nephrectomy&#xD;
&#xD;
               -  Primary tumor is considered amenable to surgical extirpation by the attending&#xD;
                  surgeon&#xD;
&#xD;
               -  Thrombosis of the inferior vena cava below the epathic veins allowed&#xD;
&#xD;
          -  No symptomatic brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Adequate hematology and coagulation&#xD;
&#xD;
          -  Amylase and lipase normal&#xD;
&#xD;
          -  Adequate hepatic, renal, and cardiac function&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  No uncontrolled hypertension and/or clinically significant cardiovascular events or&#xD;
             disease within the past 12 months&#xD;
&#xD;
          -  No other cancer within the past 5 years except adequately treated basal cell or&#xD;
             squamous cell skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior early nephrectomy due to clinical condition&#xD;
&#xD;
          -  No prior systemic therapy for renal cell carcinoma (e.g., chemotherapy, hormonal&#xD;
             therapy, interferon, interleukin-2, lymphocyte-activated killer cells, or other&#xD;
             biological response modifiers)&#xD;
&#xD;
          -  More than 12 days since prior potent CYP3A4 inducers, including any of the following:&#xD;
&#xD;
               -  Rifampin&#xD;
&#xD;
               -  Rifabutin&#xD;
&#xD;
               -  Carbamazepine&#xD;
&#xD;
               -  Phenobarbital&#xD;
&#xD;
               -  Phenytoin&#xD;
&#xD;
               -  St. John's wort&#xD;
&#xD;
               -  Efavirenz&#xD;
&#xD;
               -  Tipranavir&#xD;
&#xD;
          -  More than 7 days since prior potent CYP3A4 inhibitors, including any of the following:&#xD;
&#xD;
               -  Ketoconazole&#xD;
&#xD;
               -  Itraconazole&#xD;
&#xD;
               -  Clarithromycin&#xD;
&#xD;
               -  Erythromycin&#xD;
&#xD;
               -  Diltiazem&#xD;
&#xD;
               -  Verapamil&#xD;
&#xD;
               -  Delavirdine&#xD;
&#xD;
               -  Indinavir&#xD;
&#xD;
               -  Saquinavir&#xD;
&#xD;
               -  Ritonavir&#xD;
&#xD;
               -  Atazanavir&#xD;
&#xD;
               -  Nelfinavir&#xD;
&#xD;
          -  No other concurrent approved or investigational anticancer treatment, including&#xD;
             chemotherapy, biological response modifiers, hormonal therapy, or immunotherapy&#xD;
&#xD;
          -  No concurrent participation in any other treatment clinical trial&#xD;
&#xD;
          -  No concurrent palliative radiotherapy or surgery&#xD;
&#xD;
          -  No concurrent drugs with proarrhythmic potential, including any of the following:&#xD;
&#xD;
               -  Terfenadine&#xD;
&#xD;
               -  Quinidine&#xD;
&#xD;
               -  Procainamide&#xD;
&#xD;
               -  Disopyramide&#xD;
&#xD;
               -  Sotalol&#xD;
&#xD;
               -  Probucol&#xD;
&#xD;
               -  Bepridil&#xD;
&#xD;
               -  Haloperidol&#xD;
&#xD;
               -  Risperidone&#xD;
&#xD;
               -  Indapamide&#xD;
&#xD;
               -  Flecainide&#xD;
&#xD;
          -  Concurrent bisphosphonate therapy for metastatic bone disease allowed provided therapy&#xD;
             was initiated at least 4 weeks prior to the first dose of study drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco Venturini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale Sacro Cuore</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ospedale Sacro Cuore</name>
      <address>
        <city>Negrar</city>
        <zip>37024</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>39-045-601-3912</phone>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <study_first_submitted>February 28, 2008</study_first_submitted>
  <study_first_submitted_qc>February 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 29, 2008</study_first_posted>
  <last_update_submitted>August 9, 2013</last_update_submitted>
  <last_update_submitted_qc>August 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2013</last_update_posted>
  <keyword>stage IV renal cell cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

